Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Spyre Therapeutics, Inc.AGLE · Entity 2649 | Chief Business Officer | February 28, 2019 | March 01, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Spyre Therapeutics, Inc.
Report date February 28, 2019 · Filed March 01, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.36 · Expires 2029-02-27 | Direct | 60,000 |
Reported balance
After 2019-02-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-02-28 · Grant · Acquired 60,000 · Balance 60,000 F1: The stock option vests and becomes exercisable in 48 equal monthly installments beginning on March 28, 2019, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests and becomes exercisable in 48 equal monthly installments beginning on March 28, 2019, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
LUMOS PHARMA, INC.
Report date December 12, 2024 · Filed December 13, 2024
Section 16 reporting ended · disclosed 2024-12-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-12-12 transaction · row 1
1 source rowRow 1 · 2024-12-12 · Disposition to issuer · Disposed 8,179 · Balance 0 F1: Disposed of pursuant to that certain Agreement and Plan of Merger, dated October 22, 2024, by and between the Issuer, DPV Parent, Inc., DPV MergerSub, Inc. and Double Point Ventures LLC ("DPV") (the "Merger Agreement") in exchange for (i) $4.25 in cash per share (the "Cash Amount"), plus (ii) one non-transferable contingent value right ("CVR") per share. Each restricted stock unit ("RSU") was cancelled and will receive the Cash Amount plus one CVR per RSU. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.52 | Direct | 0 |
Reported balance
After 2024-12-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-12-12 · Disposition to issuer · Disposed 12,000 · Balance 0 F2: This option was cancelled pursuant to the Merger Agreement in exchange for (i) an amount in cash equal to the product of (x) the total number of shares underlying such option multiplied by (y) the excess of the Cash Amount over the applicable exercise price per share and (ii) one CVR for each share underlying such in-the-money option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.84 · Expires 2034-03-31 | Direct | 0 |
Reported balance
After 2024-12-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-12-12 · Disposition to issuer · Disposed 12,000 · Balance 0 F2: This option was cancelled pursuant to the Merger Agreement in exchange for (i) an amount in cash equal to the product of (x) the total number of shares underlying such option multiplied by (y) the excess of the Cash Amount over the applicable exercise price per share and (ii) one CVR for each share underlying such in-the-money option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.06 · Expires 2030-05-05 | Direct | 0 |
Reported balance
After 2024-12-12 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-12-12 · Disposition to issuer · Disposed 45,000 · Balance 0 F3: Represents an out-of-money option that was cancelled without any cash payment or issuance of CVRs being made in respect thereof pursuant to the Merger Agreement. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.02 · Expires 2032-01-31 | Direct | 0 |
Reported balance
After 2024-12-12 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-12-12 · Disposition to issuer · Disposed 12,000 · Balance 0 F3: Represents an out-of-money option that was cancelled without any cash payment or issuance of CVRs being made in respect thereof pursuant to the Merger Agreement. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.13 · Expires 2031-05-31 | Direct | 0 |
Reported balance
After 2024-12-12 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-12-12 · Disposition to issuer · Disposed 7,805 · Balance 0 F3: Represents an out-of-money option that was cancelled without any cash payment or issuance of CVRs being made in respect thereof pursuant to the Merger Agreement. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.35 · Expires 2031-01-31 | Direct | 0 |
Reported balance
After 2024-12-12 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2024-12-12 · Disposition to issuer · Disposed 8,500 · Balance 0 F3: Represents an out-of-money option that was cancelled without any cash payment or issuance of CVRs being made in respect thereof pursuant to the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to that certain Agreement and Plan of Merger, dated October 22, 2024, by and between the Issuer, DPV Parent, Inc., DPV MergerSub, Inc. and Double Point Ventures LLC ("DPV") (the "Merger Agreement") in exchange for (i) $4.25 in cash per share (the "Cash Amount"), plus (ii) one non-transferable contingent value right ("CVR") per share. Each restricted stock unit ("RSU") was cancelled and will receive the Cash Amount plus one CVR per RSU.
F2: This option was cancelled pursuant to the Merger Agreement in exchange for (i) an amount in cash equal to the product of (x) the total number of shares underlying such option multiplied by (y) the excess of the Cash Amount over the applicable exercise price per share and (ii) one CVR for each share underlying such in-the-money option.
F3: Represents an out-of-money option that was cancelled without any cash payment or issuance of CVRs being made in respect thereof pursuant to the Merger Agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 12, 2024 Filed Dec 13, 2024 21:31 UTC | LUMOS PHARMA, INC. (LUMO) · Entity 85102 | Disposition to issuerStock Option (Right to Buy) · Derivative | 8,500 | Not disclosed Strike: $17.35 | Not disclosed |
DisclosureSEC source: 0001126234-24-000114 · wk-form4_1734143462.xml · derivative · entry 7 Schuchart Aaron · CIK 0001709258 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,500 shares Expires 2031-01-31 F3 · price: Represents an out-of-money option that was cancelled without any cash payment or issuance of CVRs being made in respect thereof pursuant to the Merger Agreement. F3 · derivative.exercise_date: Represents an out-of-money option that was cancelled without any cash payment or issuance of CVRs being made in respect thereof pursuant to the Merger Agreement. Read SEC document |
| December 12, 2024 Filed Dec 13, 2024 21:31 UTC | LUMOS PHARMA, INC. (LUMO) · Entity 85102 | Disposition to issuerStock Option (Right to Buy) · Derivative | 7,805 | Not disclosed Strike: $10.13 | Not disclosed |
DisclosureSEC source: 0001126234-24-000114 · wk-form4_1734143462.xml · derivative · entry 6 Schuchart Aaron · CIK 0001709258 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,805 shares Expires 2031-05-31 F3 · price: Represents an out-of-money option that was cancelled without any cash payment or issuance of CVRs being made in respect thereof pursuant to the Merger Agreement. F3 · derivative.exercise_date: Represents an out-of-money option that was cancelled without any cash payment or issuance of CVRs being made in respect thereof pursuant to the Merger Agreement. Read SEC document |
| December 12, 2024 Filed Dec 13, 2024 21:31 UTC | LUMOS PHARMA, INC. (LUMO) · Entity 85102 | Disposition to issuerStock Option (Right to Buy) · Derivative | 12,000 | Not disclosed Strike: $10.02 | Not disclosed |
DisclosureSEC source: 0001126234-24-000114 · wk-form4_1734143462.xml · derivative · entry 5 Schuchart Aaron · CIK 0001709258 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2032-01-31 F3 · price: Represents an out-of-money option that was cancelled without any cash payment or issuance of CVRs being made in respect thereof pursuant to the Merger Agreement. F3 · derivative.exercise_date: Represents an out-of-money option that was cancelled without any cash payment or issuance of CVRs being made in respect thereof pursuant to the Merger Agreement. Read SEC document |
| December 12, 2024 Filed Dec 13, 2024 21:31 UTC | LUMOS PHARMA, INC. (LUMO) · Entity 85102 | Disposition to issuerStock Option (Right to Buy) · Derivative | 45,000 | Not disclosed Strike: $9.06 | Not disclosed |
DisclosureSEC source: 0001126234-24-000114 · wk-form4_1734143462.xml · derivative · entry 4 Schuchart Aaron · CIK 0001709258 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 45,000 shares Expires 2030-05-05 F3 · price: Represents an out-of-money option that was cancelled without any cash payment or issuance of CVRs being made in respect thereof pursuant to the Merger Agreement. F3 · derivative.exercise_date: Represents an out-of-money option that was cancelled without any cash payment or issuance of CVRs being made in respect thereof pursuant to the Merger Agreement. Read SEC document |
| December 12, 2024 Filed Dec 13, 2024 21:31 UTC | LUMOS PHARMA, INC. (LUMO) · Entity 85102 | Disposition to issuerStock Option (Right to Buy) · Derivative | 12,000 | Not disclosed Strike: $2.84 | Not disclosed |
DisclosureSEC source: 0001126234-24-000114 · wk-form4_1734143462.xml · derivative · entry 3 Schuchart Aaron · CIK 0001709258 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2034-03-31 F2 · price: This option was cancelled pursuant to the Merger Agreement in exchange for (i) an amount in cash equal to the product of (x) the total number of shares underlying such option multiplied by (y) the excess of the Cash Amount over the applicable exercise price per share and (ii) one CVR for each share underlying such in-the-money option. F2 · derivative.exercise_date: This option was cancelled pursuant to the Merger Agreement in exchange for (i) an amount in cash equal to the product of (x) the total number of shares underlying such option multiplied by (y) the excess of the Cash Amount over the applicable exercise price per share and (ii) one CVR for each share underlying such in-the-money option. Read SEC document |
| December 12, 2024 Filed Dec 13, 2024 21:31 UTC | LUMOS PHARMA, INC. (LUMO) · Entity 85102 | Disposition to issuerStock Option (Right to Buy) · Derivative | 12,000 | Not disclosed Strike: $3.52 | Not disclosed |
DisclosureSEC source: 0001126234-24-000114 · wk-form4_1734143462.xml · derivative · entry 2 Schuchart Aaron · CIK 0001709258 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires not disclosed F2 · price: This option was cancelled pursuant to the Merger Agreement in exchange for (i) an amount in cash equal to the product of (x) the total number of shares underlying such option multiplied by (y) the excess of the Cash Amount over the applicable exercise price per share and (ii) one CVR for each share underlying such in-the-money option. F2 · derivative.exercise_date: This option was cancelled pursuant to the Merger Agreement in exchange for (i) an amount in cash equal to the product of (x) the total number of shares underlying such option multiplied by (y) the excess of the Cash Amount over the applicable exercise price per share and (ii) one CVR for each share underlying such in-the-money option. F2 · derivative.expiration_date: This option was cancelled pursuant to the Merger Agreement in exchange for (i) an amount in cash equal to the product of (x) the total number of shares underlying such option multiplied by (y) the excess of the Cash Amount over the applicable exercise price per share and (ii) one CVR for each share underlying such in-the-money option. Read SEC document |
| December 12, 2024 Filed Dec 13, 2024 21:31 UTC | LUMOS PHARMA, INC. (LUMO) · Entity 85102 | Disposition to issuerCommon Stock | 8,179 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001126234-24-000114 · wk-form4_1734143462.xml · nonDerivative · entry 1 Schuchart Aaron · CIK 0001709258 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: Disposed of pursuant to that certain Agreement and Plan of Merger, dated October 22, 2024, by and between the Issuer, DPV Parent, Inc., DPV MergerSub, Inc. and Double Point Ventures LLC ("DPV") (the "Merger Agreement") in exchange for (i) $4.25 in cash per share (the "Cash Amount"), plus (ii) one non-transferable contingent value right ("CVR") per share. Each restricted stock unit ("RSU") was cancelled and will receive the Cash Amount plus one CVR per RSU. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 17:09 UTC | LUMOS PHARMA, INC. (LUMO) · Entity 85102 | GrantStock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $2.84 | $0.00 |
DisclosureSEC source: 0001126234-24-000034 · wk-form4_1712178560.xml · derivative · entry 2 Schuchart Aaron · CIK 0001709258 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2034-03-31 F5 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Plan. The option vests and becomes exercisable in a series of 48 successive equal monthly installments beginning on May 1, 2024, provided that at the relevant vesting dates the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan. The option expires ten years after the date of grant. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 17:09 UTC | LUMOS PHARMA, INC. (LUMO) · Entity 85102 | GrantCommon Stock | 1,000 | $2.84 | $2,840.00 |
DisclosureSEC source: 0001126234-24-000034 · wk-form4_1712178560.xml · nonDerivative · entry 1 Schuchart Aaron · CIK 0001709258 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,679 F1 · shares: Represents shares issued as restricted stock units ("RSUs") under the Issuer's 2009 Equity Incentive Plan (the "Plan") that were received as an award, for no consideration. The RSUs vest in a series of four successive annual installments beginning on April 1, 2025, provided in each case that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan. F2 · balance_after: Includes 174 RSUs granted under the Plan. The RSUs will vest, and shares will be delivered to the Reporting Person on February 1, 2025, provided that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan. F3 · balance_after: Includes 500 RSUs granted under the Plan. The RSUs will vest, and shares will be delivered to the Reporting Person in a series of two successive annual installments with the next installment occurring on February 1, 2025, provided in each case that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan. F4 · balance_after: Includes 750 RSUs granted under the Plan. The RSUs will vest, and shares will be delivered to the Reporting Person in a series of three successive annual installments with the next installment occurring on February 1, 2025, provided in each case that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 17:52 UTC | LUMOS PHARMA, INC. (LUMO) · Entity 85102 | Tax withholdingCommon Stock | 202 | $3.01 | $608.02 |
DisclosureSEC source: 0001126234-24-000013 · wk-form4_1707173555.xml · nonDerivative · entry 1 Schuchart Aaron · CIK 0001709258 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,679 F1 · shares: Represents shares of Common Stock withheld by the Issuer in satisfaction of its tax withholding obligation with respect to the vesting of 674 previously reported restricted stock units ("RSUs") granted to the Reporting Person. F2 · balance_after: Includes 174 RSUs previously reported as holdings of the Reporting Person granted under the Plan. The RSUs will vest, and shares will be delivered to the Reporting Person on February 1, 2025, provided that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan. F3 · balance_after: Includes 500 RSUs previously reported as holdings of the Reporting Person granted under the Plan. The RSUs will vest, and shares will be delivered to the Reporting Person in a series of two successive annual installments with the next installment occurring on February 1, 2025, provided in each case that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan. F4 · balance_after: Includes 750 RSUs previously reported as holdings of the Reporting Person granted under the Plan. The RSUs will vest, and shares will be delivered to the Reporting Person in a series of three successive annual installments with the next installment occurring on February 1, 2025, provided in each case that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan. F5 · balance_after: Includes 500 shares acquired under the Lumos Pharma, Inc. 2010 Employee Stock Purchase Plan on December 31, 2023. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 17:04 UTC | LUMOS PHARMA, INC. (LUMO) · Entity 85102 | GrantStock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $3.52 | $0.00 |
DisclosureSEC source: 0001126234-23-000018 · wf-form4_167546185913841.xml · derivative · entry 3 Schuchart Aaron · CIK 0001709258 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires not disclosed F6 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Plan. 50% of the option vests and becomes exercisable in a series of 48 successive equal monthly installments beginning on March 1, 2023, provided that at the relevant vesting dates the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan. The option expires ten years after the Date of Grant. F7 · derivative.exercise_date: The remaining 50% of the stock options vest and become exercisable in 3 substantially equal tranches on the first of the month following an increase of closing stock price, as defined as the closing stock price on Nasdaq Stock Market by at least 50%, 100% and 150%, respectively, above the closing stock on December 31, 2022, when measured over 30 consecutive calendar days, provided such increase occurs within two years of the Date of Grant, otherwise such options shall be cancelled. F8 · derivative.expiration_date: Unless otherwise disclosed, the option expires ten years after the date of grant. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 17:04 UTC | LUMOS PHARMA, INC. (LUMO) · Entity 85102 | Tax withholdingCommon Stock | 104 | $3.52 | $366.08 |
DisclosureSEC source: 0001126234-23-000018 · wf-form4_167546185913841.xml · nonDerivative · entry 2 Schuchart Aaron · CIK 0001709258 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,381 F5 · shares: Represents shares of Common Stock withheld by the Issuer in satisfaction of its tax withholding obligation with respect to the vesting of 424 previously reported restricted stock units ("RSUs") granted to the Reporting Person. F2 · balance_after: Includes 348 RSUs previously reported as holdings of the Reporting Person granted under the Plan. The RSUs will vest, and shares will be delivered to the Reporting Person in a series of two successive annual installments with the next installment occurring on February 1, 2024, provided in each case that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan. F3 · balance_after: Includes 750 RSUs previously reported as holdings of the Reporting Person granted under the Plan. The RSUs will vest, and shares will be delivered to the Reporting Person in a series of three successive annual installments with the next installment occurring on February 1, 2024, provided in each case that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan. F4 · balance_after: Includes 500 shares acquired under the Lumos Pharma, Inc. 2010 Employee Stock Purchase Plan on December 31, 2022. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 17:04 UTC | LUMOS PHARMA, INC. (LUMO) · Entity 85102 | GrantCommon Stock | 1,000 | $3.52 | $3,520.00 |
DisclosureSEC source: 0001126234-23-000018 · wf-form4_167546185913841.xml · nonDerivative · entry 1 Schuchart Aaron · CIK 0001709258 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,485 F1 · shares: Represents shares issued as restricted stock units ("RSUs") under the Issuer's 2009 Equity Incentive Plan, as amended, (the "Plan") that were received as an award, for no consideration. The RSUs vest in a series of four successive annual installments beginning on February 1, 2024, provided in each case that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan. F2 · balance_after: Includes 348 RSUs previously reported as holdings of the Reporting Person granted under the Plan. The RSUs will vest, and shares will be delivered to the Reporting Person in a series of two successive annual installments with the next installment occurring on February 1, 2024, provided in each case that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan. F3 · balance_after: Includes 750 RSUs previously reported as holdings of the Reporting Person granted under the Plan. The RSUs will vest, and shares will be delivered to the Reporting Person in a series of three successive annual installments with the next installment occurring on February 1, 2024, provided in each case that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan. F4 · balance_after: Includes 500 shares acquired under the Lumos Pharma, Inc. 2010 Employee Stock Purchase Plan on December 31, 2022. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 16:37 UTC | LUMOS PHARMA, INC. (LUMO) · Entity 85102 | GrantStock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $10.02 | $0.00 |
DisclosureSEC source: 0001126234-22-000012 · wf-form4_164392421135990.xml · derivative · entry 3 Schuchart Aaron · CIK 0001709258 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2032-01-31 F4 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Plan. The option vests and becomes exercisable in a series of 48 successive equal monthly installments beginning on March 1, 2022, provided that at the relevant vesting dates the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan. The option expires ten years after the date of grant. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 16:37 UTC | LUMOS PHARMA, INC. (LUMO) · Entity 85102 | Tax withholdingCommon Stock | 52 | $10.02 | $521.04 |
DisclosureSEC source: 0001126234-22-000012 · wf-form4_164392421135990.xml · nonDerivative · entry 2 Schuchart Aaron · CIK 0001709258 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,985 F3 · shares: Represents shares of Common Stock withheld by the Issuer in satisfaction of its tax withholding obligation with respect to the vesting of 173 previously reported restricted stock units ("RSUs") granted to the Reporting Person. F2 · balance_after: Includes 522 RSUs previously reported as holdings of the Reporting Person granted under the Plan. The RSUs will vest, and shares will be delivered to the Reporting Person in a series of three successive annual installments with the next installment occurring on February 1, 2023, provided in each case that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 16:37 UTC | LUMOS PHARMA, INC. (LUMO) · Entity 85102 | GrantCommon Stock | 1,000 | $10.02 | $10,020.00 |
DisclosureSEC source: 0001126234-22-000012 · wf-form4_164392421135990.xml · nonDerivative · entry 1 Schuchart Aaron · CIK 0001709258 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,037 F1 · shares: Represents shares issued as restricted stock units ("RSUs") under the Issuer's 2009 Equity Incentive Plan, as amended, (the "Plan") that were received as an award, for no consideration. The RSUs vest in a series of four successive annual installments beginning on February 1, 2023, provided in each case that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan. F2 · balance_after: Includes 522 RSUs previously reported as holdings of the Reporting Person granted under the Plan. The RSUs will vest, and shares will be delivered to the Reporting Person in a series of three successive annual installments with the next installment occurring on February 1, 2023, provided in each case that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan. Read SEC document |
| August 12, 2021 Filed Aug 13, 2021 16:32 UTC | LUMOS PHARMA, INC. (LUMO) · Entity 85102 | PurchaseCommon Stock | 1,700 | $7.42 | $12,614.00 |
DisclosureSEC source: 0001126234-21-000113 · wf-form4_162888671669667.xml · nonDerivative · entry 2 Schuchart Aaron · CIK 0001709258 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,037 F1 · balance_after: Includes 695 restricted stock units ("RSUs") previously reported as holdings of the Reporting Person granted under the Issuer's 2009 Equity Incentive Plan (the "Plan"). The RSUs will vest, and shares will be delivered to the Reporting Person in a series of four successive annual installments with the next installment occurring on February 1, 2022, provided in each case that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan. Read SEC document |
| August 11, 2021 Filed Aug 13, 2021 16:32 UTC | LUMOS PHARMA, INC. (LUMO) · Entity 85102 | PurchaseCommon Stock | 300 | $7.35 | $2,205.00 |
DisclosureSEC source: 0001126234-21-000113 · wf-form4_162888671669667.xml · nonDerivative · entry 1 Schuchart Aaron · CIK 0001709258 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,337 F1 · balance_after: Includes 695 restricted stock units ("RSUs") previously reported as holdings of the Reporting Person granted under the Issuer's 2009 Equity Incentive Plan (the "Plan"). The RSUs will vest, and shares will be delivered to the Reporting Person in a series of four successive annual installments with the next installment occurring on February 1, 2022, provided in each case that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan. F2 · balance_after: Includes 109 shares acquired under the Lumos Pharma, Inc. 2010 Employee Stock Purchase Plan on June 30, 2021. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 16:52 UTC | LUMOS PHARMA, INC. (LUMO) · Entity 85102 | GrantStock Option (Right to Buy) · Derivative | 7,805 | $0.00 Strike: $10.13 | $0.00 |
DisclosureSEC source: 0001126234-21-000088 · wf-form4_162275349099019.xml · derivative · entry 1 Schuchart Aaron · CIK 0001709258 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,805 Underlying: Common Stock · 7,805 shares Expires 2031-05-31 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's 2009 Equity Incentive Plan (the "Plan"). The option vests and becomes exercisable in a series of 48 successive equal monthly installments beginning on July 1, 2021, provided that at the relevant vesting dates the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan. The option expires ten years after the date of grant. Read SEC document |
| February 28, 2019 Filed Mar 1, 2019 17:09 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | GrantEmployee Stock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $8.36 | $0.00 |
DisclosureSEC source: 0001567619-19-005836 · doc1.xml · derivative · entry 1 Schuchart Aaron · CIK 0001709258 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2029-02-27 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments beginning on March 28, 2019, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| September 27, 2018 Filed Sep 28, 2018 17:11 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | SaleCommon Stock | 5,900 | $9.50 | $56,050.00 |
DisclosureSEC source: 0001567619-18-003282 · doc1.xml · nonDerivative · entry 2 Schuchart Aaron · CIK 0001709258 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Read SEC document |
| September 27, 2018 Filed Sep 28, 2018 17:11 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | SaleCommon Stock | 100 | $9.55 | $955.00 |
DisclosureSEC source: 0001567619-18-003282 · doc1.xml · nonDerivative · entry 1 Schuchart Aaron · CIK 0001709258 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,400 Read SEC document |
| August 17, 2018 Filed Aug 21, 2018 16:24 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 8,500 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0001567619-18-001566 · doc1.xml · derivative · entry 2 Schuchart Aaron · CIK 0001709258 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,500 Underlying: Common Stock · 8,500 shares Expires 2027-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option vested and became exercisable as to 1/4th of the shares subject to the option on May 22, 2018, and thereafter vests and becomes exercisable as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| August 17, 2018 Filed Aug 21, 2018 16:24 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | Exercise / conversionCommon Stock | 8,500 | $3.50 | $29,750.00 |
DisclosureSEC source: 0001567619-18-001566 · doc1.xml · nonDerivative · entry 1 Schuchart Aaron · CIK 0001709258 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 18:22 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | GrantEmployee Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $6.31 | $0.00 |
DisclosureSEC source: 0001140361-18-009664 · doc1.xml · derivative · entry 1 Schuchart Aaron · CIK 0001709258 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-02-19 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments beginning on March 20, 2018, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| August 22, 2017 Filed Aug 24, 2017 18:02 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | GrantEmployee Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $3.10 | $0.00 |
DisclosureSEC source: 0001140361-17-033207 · doc1.xml · derivative · entry 1 Schuchart Aaron · CIK 0001709258 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-08-21 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 50% of the shares subject to the option on August 22, 2018, an additional 30% of the shares subject to the option on August 22, 2019, and the remaining 20% of the shares subject to the option on August 22, 2020, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| June 16, 2017 Filed Jun 20, 2017 17:06 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | GrantEmployee Stock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0001140361-17-025613 · doc1.xml · derivative · entry 1 Schuchart Aaron · CIK 0001709258 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2027-06-15 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 1/4th of the shares subject to the option on May 22, 2018, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.